Post on 18-Jul-2020
1Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Corporate Presentation
Zwingenberg, May 29, 2020
BRAIN Group Pioneering Bioproducts
2Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
DisclaimerThis document may contain forward-looking statements. These forward-looking statements are subject to risks and
uncertainties, as they relate to future events and are based on current assumptions of the Company, which may
not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or
performance of the Company, and the development of economic and legal conditions may materially differ from the
information expressed or implied in the forward-looking statements.
The Company assumes no obligation to update or revise any forward-looking statement contained herein or to
adapt them to future events or developments. The information contained in this document has not been
independently verified. No representation or warranty expressed or implied is made as to, and no reliance should
be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein.
The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability
whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or
otherwise arising in connection with this document.
By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the
market and the market position of the Company and that you will conduct your own analysis and be solely
responsibility for forming your own view of the potential future performance of the Company’s business.
This presentation speaks as of May 29, 2020. Neither the delivery of this presentation nor any further discussions
of the Company with any of the recipients shall, under any circumstances, create any implication that there has
been no change in the affairs of the Company since such date. The term “BRAIN”, as used in this presentation
means B.R.A.I.N. Biotechnology Research and Information Network AG and its affiliates, if not otherwise
specified.
3Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
BRAIN Group at a Glance
Key facts
• Founded 1993
• 2019 revenues: 38.6 m€
• 300 staff employed
• Since 2016 listed at Frankfurt Stock Exchange
• Five operating companies
Leader in Bioeconomy
• Proven partnership track-record (>100 partnerships)
• Comprehensive proprietary BioArchive of natural solutions
(Result of >450 man years)
• Strong network with international partners and academia
• Substantial funding secured over the last 5 years: 8 m€
Growth opportunities
• New venture creation
• Pipeline of own products
• Internationalization of business
• M&A
300Employees
>100Industrial partnerships
12New product development programs
>100Specialty B2B products
>26Years of experience
4Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Our Space is “White Biotech”
Green biotech
(agricultural)
Red biotech
(medical)
Blue biotech
(marine)
White biotech
(industrial)
BIOTECHNOLOGY
Clear strategic positioning in Biotechnology
5Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Three Product Platforms
Capitalizing on synergies in technology and application
Enzymes
Microorganisms
Bioactive
Natural
Compounds
6Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Three Different Business Models
New Product
Development
Product
SalesTailor-made
Solutions
Each revenue source feeds off the others.
100 products
> 70% of BRAIN
revenue
Earnings models include:
• spin out (SolasCure)
• JV
• run ourselves
• out-license
Earnings models include:
• (IP) license income
• milestone payments
• tech access fee
• strain/molecule sale
7Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Our Solutions Address Key Sustainability Goals
Mission: Creating breakthrough B2B Bioproducts for Nutrition,
Health and the Environment
8Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Products and Solutions with Impact on Sustainability
Products and Solutions help Customers to reach SDG Goals
Ensure Access to Water and
Sanitation / Improve Water Quality
Sustainable Industry, Innovation,
Infrastructure
Sustainable Consumption and
Production Patterns
Combat Climate Change and its
Impacts
BRAIN is providing support when it comes to:
• Replacing chemicals by biological metal extraction
from e-scrap, incinerator bottom ash and other
mineralic resources
• Reducing CO2 emissions and energy consumption
• Using CO2 as raw material: capture and utilization,
e.g. for production of energy or chemical building
blocks
• Utilizing organic waste streams: e.g. for production
of energy or value compounds
• Managing pollution: e.g. soil and water detoxification
• Recycling phosphate
• Improving production time efficiency
• Transforming waste-streams into products for
unprecedented value chains
9Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Products and Solutions with Impact on Sustainability
Products and Solutions help Customers to reach SDG Goals
End Hunger, Achieve Food
Security and Improved
Nutrition
Ensure healthy Lives
and promote Well-being
• Reduce calorie density in foods while keeping
taste – with our next generation natural sweeteners
• Make food healthier by reducing salt while
retaining savor
• Replace chemical ingredients by biological ones
– e.g. in food, cosmetics (e.g. biologically effective,
aluminium-free antitranspirants, identified by our
innovative cell-based test system)
• Maintain gut health by providing functional
probiotics, avoiding antibiotics
• Reduce human suffering by treatment of open
wounds (e.g. diabetic foot syndrome) with our
enzymatic agent Aurase®
Responsible Consumption
and Production• Reducing the perishability of foodstuffs thanks
to the use of natural bioactive antimicrobials
10Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
We create breakthrough solutions supported by a profitably growing
products and services business.
Breakthrough solutions:
New-to-the-world solutions that surprise our
customers and consumers for their inventiveness and
efficacy. We do not seek to copy existing solutions.
Profitably grow business:
We realize that existing products business is key
to success. We will build the existing businesses
organically and through acquisition. Goals are to
be customer intimate, generate cash-flow, and
deepen our know-how. This may mean copying
existing solutions.
Our Vision
11Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Sugar (Substitutes)1
62 bn US $
NPD Focuses on Big Targets (Sample Global Markets)
Sugar (82% of total sweetener market)
High fructose corn syrup
Others (e.g. sugar alcohols)
Natural High IntensitySweeteners (HIS)
1 Finanzen.net 01/2018; LMC-Report 2015 & nutraceuticalsworld.com 2017, 2 industrystatsreport.com, 2020 3 WhaTech, 2018 4 PR newswire (Research and Markets) 2019 5 PR newswire, 2019 6 allied market research 2019
Salt Substitutes 2 Mining Chemicals Market 3
Wound Care 4 & Advanced Wound Care 6 Microbial Control Biocide Market 5
0.84 bn US $ ~7.5 bn US $
8.6 bn US €
19.8 bn US $ 24.8 bn US $
CAGR 4.6 %
2019 2024 E
2019
1.54 bn US $2025 E
CAGR 7.8 %
2022 E
6 bn US $2017
CAGR 4.60 %
CAGR 4.10 %
2024 E2019
10.5 bn US €8,457 mn US $ 13,944 mn US $
AWC
AWC
2018 2026 E
CAGR 6.5 %
AWC
12Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
World-class collection of compounds “BioArchive”
Highly distinguishing “Filters” to identify the best candidates
Partnership track-record and skill
Integrated Tool-set from Discovery to Commercialization
We Win Thanks to Four Core Capabilities
“Discovery”
“Monetizing”
1
2
3
4
13Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Products
&
Contract
Research
NEW
R&D
New
Solutions
EBITDA
0 M€
-5 M€
5 M€
Total BRAIN operating cash-flow in 2019/20 was -3.4 m€
We Invest 5 – 7 m€ p.a. to Create New Solutions
14Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Track-Record of Industry Partnerships
Bioactive Natural
Compounds
Enzymes Microorganisms
More than 100 exclusive partner collaborations successfully completed
Industrial
Partner*
*confidential partnerships not disclosed
15Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
#3 detergent
business globally#1 European
sugar company
#4 ingredients
supplier globally
Beiersdorf
Low temperature
detergent enzymesOptimisation
of microbial strain for
isomalt production
Skin anti-irritant
Symsitive 1609
Enzymes Microorganisms Bioactive natural
compounds
Product range
BRAIN inside
Industrial partner
Flavorpro™ 786P
flavor creation
in cheese processing
BRAIN
subsidiary
Selected Examples of “BRAIN Inside”
16Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Growing Product Sales: Top 10 Enzyme Products
< 10% 10-20% > 20%
Brand Enzyme Class Application Affiliate Growth
YOY
FlavorproTM Protease
FLAVOUR
creation
FlavorproTM Peptidase
FLAVOUR
debittering
PromodTM Protease PROTEIN modification
gluten
PromodTM Protease
PROTEIN modification
hydrolysates
DepolTM Betaglucanase
FRUIT / VEGETABLES
Naturals extraction
NATUZYM PectinaseFruit / Beverage
juice yield increase
Pectinase PolygalacturonaseFRUIT / VEGETABLES
juice yield improvement
LipomodTM Esterase
DAIRY
flavour
D-zym GlucoamylaseSTARCH / BioETOH
saccharification
D-zym Alpha-amylaseSTARCH / BioETOH
liquefaction
17Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Pipeline Partner R&D Market Own Production
Salt Taste Enhancer 1.0
Yes
Salt Taste Enhancer 2.0 Yes
DOLCE Natural Sweet Solutions No
DOLCE Natural Sweet Enhancers No
Natural Antimicrobials No
Specialty Enzymes Food Yes
Aurase Yes
Gold from Waste Streams Yes
Green Metal Mining tbd
CO2 for Value Chemicals No
NoUS-CPGC
Jap. Bev-Co.
Natural Beverages
Starch Processing Enzymes Yes
New Product Development Pipeline
BRAIN plans to be supplier of active ingredient in 7 out of 12 programs
18Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Adriaan Moelker: My 100 Day Observations
BRAIN AG Strengths
Strong team culture and team spirit
Trusting work-force
Broad and deep technology know how
Three platforms to tap into: Enzymes,
Microorganism, BioActives
Solid partnership capability and network
Some very strong current industry
partnerships
Good acquisition of Biocatalysts and spin-out
SolasCure
Cost per FTE competitive; inexpensive office
buildings
Culture of cost-awareness
Several impressive talents
Improving profitability YoY
Good IR mentality
Investor and board awareness
Creative and flexible business models, e.g.
spin-out, JV, licenses etc.
BRAIN AG Challenges
Organization Structure
Overly complex
Unclear accountabilities and responsibilities
Business
Not monetizing the efforts strongly enough
Go-to-market view and approach needs to be re-focused
Small sales force
M&A strategy and pipeline underdeveloped
Interaction with the subsidiaries needs to be institutionalized
Improve government and grant funding
Enzyme host strain development needs to be addressed
HR tools and systems
Talent management is key and needs to be strengthened
Little performance management or goal setting
Cost structure
Overheads, compared to the current revenue base
Capital Markets
Clarity on pipeline communication
Focus
Growth plans and initiatives
We will build on our strengths and communicate a growth & strategy update
latest by September
19Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
In white biotech there is no comparable business.
Creating breakthroughs is our passion and is based
on the reality of proven biotechnology and business.
BRAIN is unique
20Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Key Financials
21Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
8,810,4
21,1
22,8
24,1
27,1
38,6
19,9
0
5
10
15
20
25
30
35
40
45
FY 12/13 FY 13/14 FY 14/15 FY 15/16 FY 16/17 FY 17/18 FY 18/19 6M FY 19/20
BRAIN Revenues History
42%
12%
6%
YOY Growth
In M
io.
€
22Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Key Consolidated Financials 6M 2019/20
1 Revenues + change in inventories + other income + R&D grants2 The reconciliation from adjusted to unadjusted EBITDA can be found in the
consolidated profit and loss statement as of March 31, 2020
6M 6M 1-3M 1-3M 4-6M 4-6M
(in € million) 2019/20 2018/19 2019/20 2018/19 2019/20 2018/19
Revenues 19.9 18.5 10.3 9.4 9.6 9.1
BioScience 6.8 5.2 4.0 2.8 2.8 2.4
BioIndustrial 13.1 13.3 6.3 6.6 6.8 6.7
Total operating performance1 20.2 19.8 10.4 9.9 9.8 9.9
Adjusted EBITDA2 -0.7 -1.7 -0.2 -0,0 -0.5 -1.7
EBITDA -0.9 -1.8 -0.3 -0.1 -0.6 -1.6
EBIT -2.6 -3.2 -1.2 -0.8 -1.4 -2.4
Net result -4.6 -4.1 -2.2 -1.2 -2.3 -2.8
Operating cash flow -4.1 -2.9 -0.6 -0.1 -3.5 -2.8
31.03.2020 30.09.2019 31.12.2019
Cash 6.43 15.2 13.2
3 Solascure Ltd. Capital increase EUR1,9mln, Put AnalytiCon Discovery EUR1,6mln
major Capex Büttelborn&Cardiff EUR2,6mln, additional group Capex, negative WC swing
23Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Key Consolidated Financials 6M 2019/20
● The BRAIN Group revenues increased by 7.6% to €19.9m (PY €18.5m), organically +14.1%*
o Group generated a total operating performance (TOP) of €20.2m vs. PY €19.8m (+1.9%)
o The “BioScience” segment increased its revenues by 31.9% to €6.8m (PY €5.2m), mainly due to new
and follow-up projects
o Revenues of the “BioIndustrial” segment decreased slightly to €13.1m (-1.8%), due delays in the
commissioning of new production facilities. Organically revenues increased by 6.5%*
● The reported Group EBITDA amounts to €-0.9m (PY €-1.8m)
o The “BioIndustrial” segment has been able to increase its EBITDA Margin to 11.7% (PY 10.6%)
● The adjusted Group EBITDA amounts to €-0.7m (PY €-1.7m). Adjustments have mainly been driven by
higher employee remuneration from option accounting. Adjustments:
o €155k for personnel expenses resulting from ESOP
● The gross cash-flow has been at €-3.5m vs. PY €-3.4m, almost unchanged to the previous year
● Our Cash position as of March 31st, 2020 amounted to €6.4m
*adj. for the disposal of Monteil Cosmetics
24Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Group Revenues per Segment
• Year over year the segment BioScience performed excellent
• Revenues in the segment BioIndustrial decreased slightly due delays in the commissioning of new
production facilities. Organic growth amounted to 6.5%
• The overall BRAIN group grew organically by 14.1% YoY
5.1806.833
13.34413.102
0 €
5.000 €
10.000 €
15.000 €
20.000 €
25.000 €
6M 18/19 6M 19/20
in T
. €
Revenues segments 6M 19/20
BioScience BioIndustrial
19.935
18.525
5.1806.833
12.297
13.102
0 €
5.000 €
10.000 €
15.000 €
20.000 €
25.000 €
6M 18/19 6M 19/20
in T
. €
Revenues segments 6M 19/20 organic growth
BioScience BioIndustrial
19.935
17.478
25Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Overview of Material Expenses
• In both segment we have realized material expenses cost savings
• The material expense ratio in the BioScience segment as well as the group decreased due to the rise in
revenues
8.554
1.851
6.728
8.048
1.828
6.226
0 €
1.000 €
2.000 €
3.000 €
4.000 €
5.000 €
6.000 €
7.000 €
8.000 €
9.000 €
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
In T
. €
Material expenses 6M 19/20
43,2%
29,9%
49,3%
39,9%
24,8%
48,5%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
Material expenses ratio 6M 19/20
26Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Overview of Personnel Expenses
• Personnel expenses grew slightly compared to the previous year
• The groups adj. personnel expense ratio remains stable compared to the previous year
• In BioScience the personnel expense ratio decreased by 8%-pts. compared to the previous year
• In BioIndustrial the personnel expense ratio remained stable compared to the previous year
8.801
5.625
3.176
9.171
6.177
2.993
0 €
1.000 €
2.000 €
3.000 €
4.000 €
5.000 €
6.000 €
7.000 €
8.000 €
9.000 €
10.000 €
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
IN T
. €
44,0%
89,7%
23,3%
44,7%
81,7%
23,3%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
* adj.Perso.
Personnel expenses 6M 19/20 Personnel expenses ratio 6M 19/20
27Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Overview of Other Expenses
• In the group other expenses decreased significantly due of cost savings
• In BioScience the other expenses ratio decreased by over 5%-pts. compared to the previous year
4.217
1.879
2.340
3.840
1.7992.080
0 €
500 €
1.000 €
1.500 €
2.000 €
2.500 €
3.000 €
3.500 €
4.000 €
4.500 €
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
In T
. €
Other expenses 6M 19/20
21,3%
30,3%
17,1%19,0%
24,4%
16,2%
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
30,0%
35,0%
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
Other expenses ratio 6M 19/20
* adj. Exp.
28Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
EBITDA 6M 19/20
• The group’s EBITDA improved by 50.5% compared to the prior year
• Especially the segment BioScience strongly contributed to an improved EBITDA
• The BioIndustrial segment improved its EBITDA by 8.6% despite a decline in sales
-1.756
-3.167
1.409
-869
-2.437
1.530
-4.000 €
-3.000 €
-2.000 €
-1.000 €
0 €
1.000 €
2.000 €
BRAIN Group18/19 - 19/20
BioScience18/19 - 19/20
BioIndustrial18/19 - 19/20
In T
. €
EBITDA 6M 19/20
29Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Shareholders & Calendar
30Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Notes
• Current number of shares: 18,055,782
• Free float of ~45.0%
• Strong long term investor base
• 7,000 shareholders
• WKN 520394 / ISIN DE0005203947
• Symbol BNN
• Prime Standard; Frankfurt/M
Shareholder Structure of BRAIN
DAH Beteiligungs
GmbH
MP Beteili-
gungs-GmbH
Founders/
Management
Free Float
End of March, 2020
37.9%
8.8%8.6%
44.6%
31Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Financial Calendar FY 2019/20 and beginning FY 2020/21
May 29, 2020 Publication of the quarterly report for the period ending
March 31, 2020 (6M)
August 31, 2020 Publication of the quarterly report for the period ending
June 30, 2020 (9M)
January 14, 2021 Publication of the annual report for the period ending
September 30, 2020 (12M)
February 26, 2021 Publication of the quarterly report for the period ending
December 31, 2020 (3M)
March 10, 2021 Annual General Meeting in Zwingenberg, Germany
32Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Analysts Covering BRAIN
Analyst Company Phone number
Falko Friedrichs Deutsche Bank, Frankfurt +49 69 91 03 62 70
Pierre Corby ODDO BHF, Paris +33 1 44 51 84 04
Markus Mayer Baader Helvea, Munich +49 89 51 50 18 18
Laura López Pineda Baader Helvea, Munich +49 89 51 50 18 04
Dennis Berzhanin Pareto Securities AS, Frankfurt +49 69 58 99 7 434
Manuel Mühl DZ Bank AG, Frankfurt +49 69 7447 51438
Dr. Christian Ehmann FMR Frankfurt Main Research AG +49 69 920 389-15
33Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Thank you for
your attention.
@BRAINbiotech
BRAIN AG
BRAIN Aktiengesellschaft
Darmstädter Straße 34–36
64673 Zwingenberg, Germany
+49 (0) 6251-9331-0
www.brain-biotech.com
Your contact:
Michael Schneiders (Head of Investor Relations)
+49 (0) 6251-9331-86
MiS@brain-biotech.com
34Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0
Management
• Diploma in Business Administration
• Year of birth: 1965
• Joined BRAIN in 2018
• 20+ y of finance leadership
experience as CFO and CEO in
listed companies
• Successful in market cap &
revenue growth
• Asset management, M&A
Manfred Bender
(CFO)
• Master of Business Administration
• Year of birth: 1965
• Joined BRAIN in 2018
• 20+ y international industry expertise
• Product development &
industrial transactions
• Strategy & portfolio management
Ludger Roedder
(CBO)
• Master of Business Administration
• Year of birth 1964
• Joined BRAIN in Feb. 2020
• 20+ y of professional experience in
industrial biotechnology innovation
• Successful in terms of innovation &
revenue
• Extensive global experience in all
key industrial enzyme segments
Adriaan Moelker
(CEO)
35Pioneering Bioproducts. © BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0